Mer­ck shakes hands with Ac­celeron; Fi­nal­ly, a pill for Covid-19; The past and fu­ture of con­tract re­search; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

You may re­mem­ber from the be­gin­ning of this year that End­points News’ 2021 plan is to go broad­er and deep­er. As part of that ef­fort, we will be launch­ing a new week­ly newslet­ter — End­points Mar­ket­ing Rx — to cov­er all things phar­ma mar­ket­ing. You can sign up the same way some of you signed up for this re­port: by vis­it­ing your read­er pro­file.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER